FDA panel votes down broader use of Eisai's Dacogen; Zydus, Claris to get FDA check-backs at troubled plants;

@FiercePharma: Will mid-2012 be the turning point for European pharma stocks? Maybe so, WSJ says. Item | Follow @FiercePharma

> Eisai and its partner Astex Pharmaceuticals failed to convince an FDA advisory panel that use of their injectable drug Dacogen should be broadened to patients with acute myeloid leukemia. Item

> The Securities and Exchange Commission charged a former Takeda Pharmaceutical employee with profiting on inside information about the drugmaker's deal to acquire Millennium Pharmaceuticals. Story

> Officials at India's Zydus Cadila and Claris Lifesciences, recently cited for manufacturing shortfalls, are expecting follow-up visits from FDA inspectors this month, The Economic Times says. Article

> Vice President Joe Biden, a Roman Catholic, said White House officials are working to address the Roman Catholic Church's concerns about new insurance coverage rules on contraceptives and expressed faith that the fight would be resolved. News

> Greek hospitals are fighting a superbacteria resistant even to the most powerful antibiotics, a development exacerbated by short staffing. Piece

> AstraZeneca ($AZN) bought back 335,195 shares at 3,001 pence each as part of its ongoing repurchase program. Report

Biotech News

@FierceBiotech: U.S.-based EMC to found Russian cloud-computing, 'Big Data' hub in the Skolkovo Foundation's Innovation Hub. Story | Follow @FierceBiotech

@JohnCFierce: This mouse study on Alzheimer's and bexarotene grabbing lots of headlines. Scientists sound level headed about it. Article | Follow @JohnCFierce

@FierceMedDev: Deal talk: Roche, Glencore spark hope of European M&A revival. Item via @reuters | Follow @FierceMedDev

@MarkHFierce: A patient's genetics could possibly guide TB treatment, it turns out. Another win for gene sequencing? More | Follow @MarkHFierce

> FDA maps out long-awaited rules for the biosimilars business. News

> High price of failure drives drug development costs into the stratosphere. Article

And Finally... Eisai's skin cancer drug Targretin reversed signs and symptoms of Alzheimer's disease in a mouse study. More

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.